RC Fornax PLC (AIM:RCFX) says it’s well placed as the UK reshapes defence spending. It’s bidding across seven frameworks and has three major agreements in advanced talks. The group joined Aurora’s Evolve network in January and won a UK public sector space contract. A December fundraise added £2.1 million, with £4.5 million in firm FY26 sales visibility. Blencowe Resources PLC (LSE:BRES) reported more thick, near-surface graphite hits at the Iyan deposit in Uganda. A maiden JORC resource is now expected i ...

Cory Kasimov from Evercore ISI set a price target of $115 for NASDAQ:ACLX, indicating a slight 1.04% difference from its current trading price.Gilead Sciences plans to acquire Arcellx for up to $7.8 billion, aiming to enhance its cancer treatment portfolio.The acquisition news has led to a significant increase in ACLX's stock price, soaring 77.8% in premarket trading and reflecting a 77.50% rise to $113.80.Arcellx, listed on the NASDAQ:ACLX, is a biotechnology company focused on developing innovative cancer ...

Market Overview - The U.S. markets experienced a mixed day, with a focus on the U.S. 2-year yield rising by four basis points following a Supreme Court ruling that raised questions about inflation and interest rates [2][6] - Gold prices increased as investors reacted to the risk-off sentiment in the market, while tech stocks, particularly in the software sector, saw declines of approximately 1.5% [2][4] Technology Sector - The software sector is facing significant pressure, with fears that AI tools may replace traditional software suites, leading to a 30% decline in an index of stocks including Salesforce and Adobe since their record highs [4][70] - Companies like IBM have seen substantial stock declines, with IBM down over 13% amid concerns about AI disruption [70][77] Payment and Delivery Services - PayPal's stock rose nearly 5% due to takeover interest, contrasting with the broader tech sector's struggles [3] - Delivery service companies such as DoorDash and Uber are facing challenges as hypothetical scenarios suggest that AI could disrupt their business models, contributing to stock declines [5][71] Tariff and Trade Implications - The Supreme Court ruling on tariffs has created uncertainty, particularly for major importers like Home Depot and TJX, as the market grapples with the implications of potential tariff changes [6][80] - The Attorney General of Nevada indicated that states are considering actions to recover tariffs collected, which could amount to hundreds of billions of dollars [22][23] Economic Indicators - The current economic environment shows signs of growth, with global growth rates around 2.5% and 3% including emerging markets, while inflation is gradually decreasing [10][17] - The bond market is experiencing a steepening yield curve, driven by long-term inflationary concerns and an excess supply of government debt [12][14] Trucking and Transportation Sector - The trucking industry is witnessing structural changes, with a significant reduction in driver availability leading to higher rates and potential long-term impacts on capacity [57][68] - Demand for transportation services is still down year-over-year, but there are positive indicators such as increased trade volumes and a projected recovery in the second half of the year [59][63]

Core Insights - ImmunityBio, Inc. is focused on developing innovative immunotherapy treatments, with its flagship product Anktiva playing a crucial role in treating cancers unresponsive to traditional therapies [1] - The company has a market capitalization of approximately $9.57 billion, reflecting its growth potential and market confidence in its cancer treatment solutions [5] Financial Performance - H.C. Wainwright set a price target of $15 for IBRX, indicating a potential upside of 54.56% from its current price of $9.71 [2][6] - Anktiva reported a remarkable 700% sales increase in 2025 and a 20% quarter-over-quarter growth in the fourth quarter [3][6] - Despite a negative earnings per share of $0.06, the company has shown profitability improvement for three consecutive quarters, contributing to a stock price increase of five times in 2026 [3] Product and Market Strategy - The Cancer BioShield platform and Anktiva biologic product are key to ImmunityBio's strategy, stimulating natural killer cells, cytotoxic T cells, and memory T cells to help patients combat various cancers [4] - The majority of revenue comes from U.S. sales of Anktiva, particularly for bladder cancer cases unresponsive to Bacille Calmette-Guérin treatment [4]

Core Viewpoint - Arcellx, Inc. is experiencing significant market activity due to Gilead Sciences' planned acquisition, which is valued at $7.8 billion, marking a pivotal moment for the company and its stock performance [2][4]. Group 1: Stock Performance - Arcellx's stock surged approximately 80% in premarket trading following the acquisition announcement, with the current stock price at $113.81, reflecting a 77.52% increase and a $49.70 change [2]. - The stock has fluctuated between $113.80 and $114.26, marking its highest price over the past year, compared to a previous low of $47.86, indicating substantial growth [3]. Group 2: Acquisition Details - Gilead Sciences plans to acquire Arcellx in an all-cash deal valued at $7.8 billion, which is Gilead's largest acquisition since 2020, aimed at enhancing its cancer treatment portfolio [2]. - The acquisition involves acquiring the remaining shares of Arcellx, further solidifying Gilead's position in the biotech sector [4]. Group 3: Market Capitalization and Trading Volume - Arcellx's market capitalization is approximately $6.58 billion, with a trading volume of around 18.59 million shares, reflecting strong investor interest following the acquisition news [4].

Strategic reset positions Galapagos for long-term value creation Robust 2025 year-end cash and financial investments of €3.0 billion and ongoing collaboration with Gilead enable flexibility to execute on a business development-led growth strategy 2026 year-end cash expected to be in the range of €2.775 to €2.850 billion, with reduced cell therapy one-time restructuring cash costs of €25 million to an updated range of €125 to €175 million Management to host conference call tomorrow, February 24, 2026, at 14: ...

CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will announce its fourth quarter and full year 2025 financial results and a new liver-targeted genetic disease program on an investor webcast on Tuesday, February 24, 2026, at 8:00 a.m. ET.The live webcast will be available in the investor section of the company's website at www.beamtx.com and will be ...

CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will announce its fourth quarter and full year 2025 financial results and a new liver-targeted genetic disease program on an investor webcast on Tuesday, February 24, 2026, at 8:00 a.m. ET.The live webcast will be available in the investor section of the company's website at www.beamtx.com and will be ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston Bi ...

Tandem Diabetes Care, Inc. ( TNDM ) beat out expectations in Q4 '25. GAAP EPS came in at -$0.01, which was actually $0.05 above the consensus. Elsewhere, revenue for the quarter hit $290.4 million, up about 2.8% year-over-year and $13.16 million ahead of forecasts. There wereI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic rese ...